| GSK Stock | | | USD 41.24 0.65 1.60% |
This module uses fundamental data of GlaxoSmithKline PLC to approximate its Piotroski F score. GlaxoSmithKline PLC F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of GlaxoSmithKline PLC ADR. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about GlaxoSmithKline PLC financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out
GlaxoSmithKline PLC Altman Z Score,
GlaxoSmithKline PLC Correlation,
GlaxoSmithKline PLC Valuation, as well as analyze
GlaxoSmithKline PLC Alpha and Beta and
GlaxoSmithKline PLC Hype Analysis.
At this time, GlaxoSmithKline PLC's
Cash Flow To Debt Ratio is quite stable compared to the past year. At this time, GlaxoSmithKline PLC's
PB Ratio is quite stable compared to the past year.
Free Cash Flow Per Share is expected to rise to 1.06 this year, although
Book Value Per Share will most likely fall to 2.26.
At this time, it appears that GlaxoSmithKline PLC's Piotroski F Score is Strong. Although some professional money managers and academia have recently criticized
Piotroski F-Score model, we still consider it an effective method of
predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
7.0
Piotroski F Score - Strong
| Change in Return on Assets | |
| Cash Flow Return on Assets | |
| Current Quality of Earnings (accrual) | |
| Long Term Debt Over Assets Change | Higher Leverage| Focus | |
| Change In Outstending Shares | |
GlaxoSmithKline PLC Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to GlaxoSmithKline PLC is to make sure GlaxoSmithKline is not a subject of accounting manipulations and runs a healthy internal audit department. So, if GlaxoSmithKline PLC's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if GlaxoSmithKline PLC's financial numbers are properly reported.
GlaxoSmithKline PLC ADR F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical
financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between GlaxoSmithKline PLC's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards GlaxoSmithKline PLC in a much-optimized way.
Click cells to compare fundamentals
About GlaxoSmithKline PLC Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled
Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
GlaxoSmithKline PLC Current Valuation Drivers
We derive many important indicators used in calculating different scores of GlaxoSmithKline PLC from analyzing GlaxoSmithKline PLC's financial statements. These drivers represent accounts that assess GlaxoSmithKline PLC's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of GlaxoSmithKline PLC's important valuation drivers and their relationship over time.
| | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) |
| Market Cap | | 140.2B | 107.2B | 104.6B | 117.3B | 118.1B | 124.0B |
| Enterprise Value | | 166.0B | 128.0B | 124.5B | 134.6B | 133.2B | 139.8B |
About GlaxoSmithKline PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of GlaxoSmithKline PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our
fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectWhen determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company
management, corporate governance, and ethical practices play a significant role. A
comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock.
Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock: Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to
measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to
predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost
the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth | Dividend Share | Earnings Share | Revenue Per Share | Quarterly Revenue Growth |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine
if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.